Coffee, CYP1A2 genotype, and risk of myocardial infarction

被引:318
|
作者
Cornelis, MC
El-Sohemy, A
Kabagambe, EK
Campos, H
机构
[1] Univ Toronto, Dept Nutr Sci, Toronto, ON M5S 3E2, Canada
[2] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA
[3] Univ Costa Rica, Ctr Centroamer Poblac, San Pedro Montes de Oca, Costa Rica
来源
关键词
D O I
10.1001/jama.295.10.1135
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The association between coffee intake and risk of myocardial infarction (MI) remains controversial. Coffee is a major source of caffeine, which is metabolized by the polymorphic cytochrome P450 1A2 (CYP1A2) enzyme. Individuals who are homozygous for the CYP1A2*1A allele are "rapid" caffeine metabolizers, whereas carriers of the variant CYP1A2*1F are "slow" caffeine metabolizers. Objective To determine whether CYP1A2 genotype modifies the association between coffee consumption and risk of acute nonfatal MI. Design, Setting, and Participants Cases (n = 2014) with a first acute nonfatal MI and population-based controls (n = 2014) living in Costa Rica between 1994 and 2004, matched for age, sex, and area of residence, were genotyped by restriction fragment length polymorphism polymerase chain reaction. A food frequency questionnaire was used to assess the intake of caffeinated coffee. Main Outcome Measure Relative risk of nonfatal MI associated with coffee intake, calculated using unconditional logistic regression. Results Fifty-five percent of cases (n = 1114) and 54% of controls (n = 1082) were carriers of the slow *1F allele. For carriers of the slow *1F allele, the multivariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) of nonfatal MI associated with consuming less than 1, 1, 2 to 3, and 4 or more cups of coffee per day were 1.00 ( reference), 0.99 (0.69-1.44), 1.36 (1.01-1.83), and 1.64 (1.14-2.34), respectively. Corresponding ORs ( 95% CIs) for individuals with the rapid *1A/*1A genotype were 1.00, 0.75 (0.51-1.12), 0.78 (0.56-1.09), and 0.99 (0.66-1.48) (P = .04 for gene X coffee interaction). For individuals younger than the median age of 59 years, the ORs ( 95% CIs) associated with consuming less than 1, 1, 2 to 3, or 4 or more cups of coffee per day were 1.00, 1.24 (0.71-2.18), 1.67 (1.08-2.60), and 2.33 (1.39-3.89), respectively, among carriers of the *1F allele. The corresponding ORs ( 95% CIs) for those with the *1A/*1A genotype were 1.00, 0.48 (0.26-0.87), 0.57 (0.35-0.95), and 0.83 (0.46-1.51). Conclusion Intake of coffee was associated with an increased risk of nonfatal MI only among individuals with slow caffeine metabolism, suggesting that caffeine plays a role in this association.
引用
收藏
页码:1135 / 1141
页数:7
相关论文
共 50 条
  • [41] Coffee Consumption and CYP1A2 Polymorphism Involvement in Type 2 Diabetes in a Romanian Population
    Popa, Laura Claudia
    Farcas, Simona Sorina
    Andreescu, Nicoleta Ioana
    JOURNAL OF PERSONALIZED MEDICINE, 2024, 14 (07):
  • [42] Inducibility of CYP1A2 by orneprazole in vivo related to the genetic polymorphism of CYP1A2
    Han, XM
    Ouyang, DS
    Chen, XP
    Shu, Y
    Jiang, CH
    Tan, ZR
    Zhou, HH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) : 540 - 543
  • [43] The influence of CYP1A1 and CYP1A2 polymorphisms on stroke risk in the Chinese population
    Yan Mao
    Lin Yang
    Qian Chen
    Guoqing Li
    Yao Sun
    Jiamin Wu
    Zichao Xiong
    Yuanwei Liu
    Haiyue Li
    Jianfeng Liu
    Yong Zhang
    Lipids in Health and Disease, 19
  • [44] Analysis of NAT and CYP1A2 phenotypes and NAT2* genotype by capillary electrophoresis
    Meacher, DM
    Rasmussen, RE
    Menzel, DB
    BIOMARKERS, 1998, 3 (03) : 205 - 218
  • [45] Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia
    Perera, Vidya
    Gross, Annette S.
    Polasek, Thomas M.
    Qin, Yan
    Rao, Gauri
    Forrest, Alan
    Xu, Junzhe
    McLachlan, Andrew J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (09) : 1115 - 1137
  • [46] Role of CYP1A2 in the hepatotoxicity of acetaminophen:: Investigations using Cyp1a2 null mice
    Tonge, RP
    Kelly, EJ
    Bruschi, SA
    Kalhorn, T
    Eaton, DL
    Nebert, DW
    Nelson, SD
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1998, 153 (01) : 102 - 108
  • [47] Identification of the contact region responsible for the formation of the homomeric CYP1A2•CYP1A2 complex
    Saha, Aratrika
    Connick, J. Patrick
    Reed, James R.
    Lott, Charles S.
    Backes, Wayne L.
    BIOCHEMICAL JOURNAL, 2021, 478 (11) : 2163 - 2178
  • [48] CYP1A2 phenotype and genotype in a population from the Carboniferous Region of Coahuila, Mexico
    Castorena-Torres, F
    Mendoza-Cantú, A
    de León, MB
    Cisneros, B
    Zapata-Pérez, O
    López-Carrillo, L
    Salinas, JE
    Albores, A
    TOXICOLOGY LETTERS, 2005, 156 (03) : 331 - 339
  • [49] Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM
    Amin, N.
    Byrne, E.
    Johnson, J.
    Chenevix-Trench, G.
    Walter, S.
    Nolte, I. M.
    Vink, J. M.
    Rawal, R.
    Mangino, M.
    Teumer, A.
    Keers, J. C.
    Verwoert, G.
    Baumeister, S.
    Biffar, R.
    Petersmann, A.
    Dahmen, N.
    Doering, A.
    Isaacs, A.
    Broer, L.
    Wray, N. R.
    Montgomery, G. W.
    Levy, D.
    Psaty, B. M.
    Gudnason, V.
    Chakravarti, A.
    Sulem, P.
    Gudbjartsson, D. F.
    Kiemeney, L. A.
    Thorsteinsdottir, U.
    Stefansson, K.
    Van Rooij, F. J. A.
    Aulchenko, Y. S.
    Hottenga, J. J.
    Rivadeneira, F. R.
    Hofman, A.
    Uitterlinden, A. G.
    Hammond, C. J.
    Shin, S-Y
    Ikram, A.
    Witteman, J. C. M.
    Janssens, A. C. J. W.
    Snieder, H.
    Tiemeier, H.
    Wolfenbuttel, B. H. R.
    Oostra, B. A.
    Heath, A. C.
    Wichmann, E.
    Spector, T. D.
    Grabe, H. J.
    Boomsma, D. I.
    MOLECULAR PSYCHIATRY, 2012, 17 (11) : 1116 - 1129
  • [50] Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM
    N Amin
    E Byrne
    J Johnson
    G Chenevix-Trench
    S Walter
    I M Nolte
    J M Vink
    R Rawal
    M Mangino
    A Teumer
    J C Keers
    G Verwoert
    S Baumeister
    R Biffar
    A Petersmann
    N Dahmen
    A Doering
    A Isaacs
    L Broer
    N R Wray
    G W Montgomery
    D Levy
    B M Psaty
    V Gudnason
    A Chakravarti
    P Sulem
    D F Gudbjartsson
    L A Kiemeney
    U Thorsteinsdottir
    K Stefansson
    F J A van Rooij
    Y S Aulchenko
    J J Hottenga
    F R Rivadeneira
    A Hofman
    A G Uitterlinden
    C J Hammond
    S-Y Shin
    A Ikram
    J C M Witteman
    A C J W Janssens
    H Snieder
    H Tiemeier
    B H R Wolfenbuttel
    B A Oostra
    A C Heath
    E Wichmann
    T D Spector
    H J Grabe
    D I Boomsma
    Molecular Psychiatry, 2012, 17 : 1116 - 1129